Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announces the successful close of its acquisition of Mersana Therapeutics, Inc., (NASDAQ: MRSN) (“Mersana”) following completion of all conditions of the tender offer to acquire all outstanding shares of Mersana at a price of $25 per share in cash, plus one non-tradable contingent value right (“CVR”) per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash.
Read the full article: Day One Completes Acquisition of Mersana Therapeutics //
Source: https://www.globenewswire.com/news-release/2026/01/06/3213738/0/en/Day-One-Completes-Acquisition-of-Mersana-Therapeutics.html?_gl=1*1j3ntpr*_up*MQ..*_ga*NTM0MzIxMzkwLjE3Njc3MDk1NDM.*_ga_ERWPGTJ5X8*czE3Njc3MDk1NDMkbzEkZzAkdDE3Njc3MDk1NDMkajYwJGwwJGgw